Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.). This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch. ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.   ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning. 

Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM).

Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development services and research tracers for use in clinical trials.

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.

Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022.

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of studies evaluating CAIX expression in cancers other than clear cell renal cell carcinoma (ccRCC), supporting Telix’s goal to rapidly expand the CAIX program into other indications beyond kidney cancer.